





- (51) **International Patent Classification:**
A61K 31/517 (2006.01) A61P 35/00 (2006.01)
C07D 239/70 (2006.01)
- (21) **International Application Number:**
PCT/US2012/031671
- (22) **International Filing Date:**
30 March 2012 (30.03.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/470,803 1 April 2011 (01.04.2011) US
61/470,624 1 April 2011 (01.04.2011) US
- (71) **Applicant (for all designated States except US):** GEN-
ENTECH, INC. [US/US]; 1 DNA Way, South San Fran-
cisco, California 94080-4990 (US).
- (72) **Inventor; and**
- (73) **Applicant :** NANNINI, Michelle [US/US]; 1 DNA Way,
South San Francisco, California 94080 (US).
- (74) **Agents:** VIKSNINS, Ann, S., et al.; VIKSNINS HARRIS
& PADYS PLLP, P.O. Box 111098, St. Paul, Minnesota
55111-1098 (US).
- (75) **Inventor/Applicant (for US only):** SAMPATH, Deepak
[US/US]; 1 DNA Way, South San Francisco, California
94080 (US).
- (81) **Designated States (unless otherwise indicated, for every
kind of national protection available):** AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every
kind of regional protection available):** ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,

[Continued on next page]

(54) **Title:** COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE

FIG 1 GDC-0068 + erlotinib in NCI-H2122 NSCL Xenographs



(57) **Abstract:** The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*